Granules India’s Gagillapur facility has been inspected by US Food and Drug Administration (USFDA) last week and the inspection concluded with no observations. The inspection was triggered by one of the applicant’s ANDA filing.
Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
